The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers

Hereditary Cancer in Clinical Practice

Katherine M.A. Rogers¹  Helen Cavanagh¹ 

[1] School of Nursing and Midwifery, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, N. Ireland

关键词: Stomach cancer;    Pancreatic cancer;    Prostate cancer;    Non-breast/ovarian cancers;    BRCA2;    BRCA1;   

Others  :  1224912
DOI  :  10.1186/s13053-015-0038-x

 received in 2015-02-02, accepted in 2015-07-28,  发布年份 2015

【 摘 要 】

The association of germline mutations in the breast cancer susceptibility gene 1 (BRCA1) and the breast cancer susceptibility gene 2 (BRCA2) with the development of breast and ovarian cancers have been widely researched and recognised. It is known that these genes function at multiple sites in the body. Research has subsequently evolved into the connection of BRCA1/2 with cancers at other sites within the body. This review examines the association of BRCA1/2 germline gene mutations with prostate, pancreatic and stomach cancers. An extensive literature search revealed conflicting findings regarding the association of BRCA1/2 gene mutations with these cancers. Most studies suggest that there is an association between BRCA1/2 mutations and carcinoma of the prostate, pancreas and stomach, but some reports propose that such a correlation may be due to factors other than possessing a mutated BRCA1/2 gene, and other associations may be revealed as further epidemiological information becomes available. The review concludes that as more knowledge arises about the mechanisms of BRCA1/2 gene mutations, it should pave the way for future screening programmes to be applied effectively.

【 授权许可】

   
2015 Cavanagh and Rogers.

【 参考文献 】

• [1]Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006; 25:5864-5874.
• [2]Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004; 95:866-871.
• [3]Kumar P, Clark ML. Kumar and Clark's Clinical Medicine, 8e: Saunders Ltd., London. 2012.
• [4]Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006; 34:1416-1426.
• [5]Berger E. New finding may unlock secrets of BRCA mutations. 2010. Available at: http://www.cancer.org/cancer/news/news/finding-may-unlock-secrets-of-brca-mutations. Acessed 30th July 2015.
• [6]Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al.. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266:66-71.
• [7]Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D et al.. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265:2088-2090.
• [8]NCI. BRCA1 & BRCA2: Cancer Risk & Genetic Testing. 2014. Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Acessed 30th July 2015.
• [9]NCI. Genetics of Breast and Ovarian Cancer (PDQ®). 2014. Available at: http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1. Acessed 30th July 2015.
• [10]Breast cancer risk factors. Cancer Research, UK; 2014.
• [11]Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010; 103:918-924.
• [12]Breast cancer Key Facts. Cancer Research, UK; 2014.
• [13]Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K. Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed). 2014; 6:15-30.
• [14]Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007; 99:929-935.
• [15]Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010; 16:2115-2121.
• [16]Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet. 2004; 129c:65-73.
• [17]Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008; 99:371-374.
• [18]Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers, Breast Cancer Linkage Consortium. Lancet. 1994; 343:692-695.
• [19]Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94:1358-1365.
• [20]Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91:1310-1316.
• [21]Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer. 1974; 34:1102-1107.
• [22]Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst. 1992; 84:1114-1117.
• [23]Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992; 305:855-857.
• [24]Agalliu I, Gern R, Leanza S, Burk RD. Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations. 2009.
• [25]Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, Ostrander EA. Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer. 2007.
• [26]Bermejo JL, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. 2004.
• [27]Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003; 72:1-12.
• [28]Pancreatic cancer statistics. Cancer Research, UK; 2014.
• [29]Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012; 118:493-499.
• [30]Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014; 120:1960-1967.
• [31]Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007; 56:601-605.
• [32]Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer. 2004; 3:233-240.
• [33]Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer. 2002; 31:99-106.
• [34]Axilbund JE, Argani P, Kamiyama M, Palmisano E, Raben M, Borges M, Brune KA, Goggins M, Hruban RH, Klein AP. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009; 8:131-135.
• [35]Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet. 2002; 39:457-462.
• [36]Kim DH, Crawford B, Ziegler J, Beattie MS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer. 2009; 8:153-158.
• [37]Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68:700-710.
• [38]Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94:1365-1372.
• [39]Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, Gorski B, Cybulski C, Debniak T, Kowalska E, Starzynska T, Lawniczak M, Narod S, Lubinski J. A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet. 2003; 11:955-958.
• [40]Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002; 87:888-891.
• [41]Schlebusch CM, Dreyer G, Sluiter MD, Yawitch TM, van den Berg HJ, van Rensburg EJ. Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. S Afr Med J. 2010; 100:113-117.
• [42]Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, Van Houwelingen JC, Van't Veer LJ, Rookus MA, Van Leeuwen FE. Netherlands Collaborative Group on Hereditary Breast C. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005; 42:711-719.
• [43]Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001; 84:478-481.
• [44]Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015; 121:269-275.
• [45]Daly PA, Nolan C, Green A, Ormiston W, Cody N, McDevitt T, O'HIci B, Byrne D, McDermott E, Carney DN, O'Higgins N, Barton DE. Predictive testing for BRCA1 and 2 mutations: a male contribution. Ann Oncol. 2003; 14:549-553.
• [46]Hallowell N, Ardern-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, Watson M. Men's decision-making about predictive BRCA1/2 testing: the role of family. J Genet Couns. 2005; 14:207-217.